Since 1995, Aravis has invested in over 80 Biotechnology companies and currently has two life science-focused funds:
Investment Focus: Bridging the gap from pre-clinic to clinic
Aravis' distinctive competence in assessing scientific risks, besides other risks, allows the selection of pre-proof of concept (i.e. platform technologies, late pre-clinical and early clinical) companies and turnaround situations offering outstanding risk-return profiles. Current investment interests focus on cross-border deals as well as companies working in the therapeutic areas of Immunology, Inflammation, Oncology and CNS.
International Network
Aravis' worldwide network of partners opens doors in a number of geographic locations. Our cooperation with 5AM Ventures in Menlo Park, California, puts Aravis in a unique position to syndicate transatlantic deals. Furthermore, Aravis' close ties with the pharmaceutical, biotechnology and life science industry provides an excellent platform for worldwide interactions.
This position offers our portfolio companies in Europe, the US and in Asia highly leveraged tools and hands-on assistance in the areas of recruitment, M&A, marketing and finance.